IntroductionInflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, relapsing, and incurable disease with low mortality. As IBD predominantly affects young adults and carries a lifetime morbidity and low mortality, the disease places a considerable burden on public health and health‐care resources. Previous studies have demonstrated that the direct and indirect costs of IBD are considerably high. In two large population‐based studies from North America, the total IBD‐associated health‐care costs were estimated as $2.8 billion in Canada and $6.3 billion in the USA (US) per year. Additionally, the cost profile of IBD care has changed over time. Because highly effective biological therapies such as anti‐tumor necrosis factor (TNF) agents have been developed, the health‐care cost of IBD has shifted from hospitalization and surgery to anti‐TNF therapy in Europe.The incidence of IBD in Asia has risen steadily over the past few decades. A nationwide population‐based study of Korea showed that the mean annual incidence of UC was 4.6 per 100 000 and that of CD was 6.2 per 100 000 from 2006 to 2012. Cumulative epidemiologic data from Korea have showed that the incidence of IBD has increased about 10‐fold over two decades in Korea.
Journal of Gastroenterology and Hepatology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera